TY - JOUR
T1 - Statin drugs, serum cholesterol, and prostate-specific antigen in the national health and nutrition examination survey 2001-2004
AU - Mondul, Alison M.
AU - Selvin, Elizabeth
AU - De Marzo, Angelo M.
AU - Freedland, Stephen J.
AU - Platz, Elizabeth A.
N1 - Funding Information:
Acknowledgments Dr. Mondul was supported by a National Research Service Award (T32 CA009314) from the National Cancer Institute, National Institutes of Health. Dr. Selvin was supported by a grant (K01 DK076595) from the National Institutes of Digestive, Diabetes, and Kidney Diseases, National Institutes of Health.
PY - 2010/5
Y1 - 2010/5
N2 - Purpose We evaluated the associations of statins and serum cholesterol with PSA to understand whether the inverse associations of statins and low cholesterol with aggressive prostate cancer are explained by detection bias. Methods We analyzed data from 2,574 men aged ≥40 years without prostate cancer in The National Health and Nutrition Examination Survey 2001-2004. We estimated multivariable-adjusted geometric mean PSA by statin use and cholesterol quintiles. To limit the influence of correlates of statin use and cholesterol on PSA, we stratified by comorbidities. Results Statin users had a non-statistically significantly lower PSA than non-users (0.90 vs. 0.95 ng/mL, p = 0.22), especially in men without comorbidities (n = 1,680; 0.86 vs. 0.99 ng/mL p = 0.02). In men with comorbidities, statin users had a non-statistically significantly higher PSA than non-users (0.91 vs. 0.83 ng/mL, p = 0.14). Men with lower cholesterol had lower PSA (bottom vs. top quintile: 0.92, 1.02 ng/mL, p-trend = 0.06). Conclusion Statin users and men with lower cholesterol may have lower PSA. If so, the probability of detecting asymptomatic prostate cancer might be lower at present, but these cases might be more likely to be diagnosed at an advanced stage in the future. Thus, PSA-associated bias is unlikely to explain the inverse association of statins with advanced prostate cancer.
AB - Purpose We evaluated the associations of statins and serum cholesterol with PSA to understand whether the inverse associations of statins and low cholesterol with aggressive prostate cancer are explained by detection bias. Methods We analyzed data from 2,574 men aged ≥40 years without prostate cancer in The National Health and Nutrition Examination Survey 2001-2004. We estimated multivariable-adjusted geometric mean PSA by statin use and cholesterol quintiles. To limit the influence of correlates of statin use and cholesterol on PSA, we stratified by comorbidities. Results Statin users had a non-statistically significantly lower PSA than non-users (0.90 vs. 0.95 ng/mL, p = 0.22), especially in men without comorbidities (n = 1,680; 0.86 vs. 0.99 ng/mL p = 0.02). In men with comorbidities, statin users had a non-statistically significantly higher PSA than non-users (0.91 vs. 0.83 ng/mL, p = 0.14). Men with lower cholesterol had lower PSA (bottom vs. top quintile: 0.92, 1.02 ng/mL, p-trend = 0.06). Conclusion Statin users and men with lower cholesterol may have lower PSA. If so, the probability of detecting asymptomatic prostate cancer might be lower at present, but these cases might be more likely to be diagnosed at an advanced stage in the future. Thus, PSA-associated bias is unlikely to explain the inverse association of statins with advanced prostate cancer.
KW - Cholesterol
KW - Cross-sectional studies
KW - Hydroxymethylglutaryl- CoA reductases
KW - Prostate-specific antigen
KW - Prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=77955286539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955286539&partnerID=8YFLogxK
U2 - 10.1007/s10552-009-9494-9
DO - 10.1007/s10552-009-9494-9
M3 - Article
C2 - 20072809
AN - SCOPUS:77955286539
SN - 0957-5243
VL - 21
SP - 671
EP - 678
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 5
ER -